FDA Approves Joenja for Pediatric APDS
Analysis based on 6 articles · First reported Sep 11, 2026 · Last updated Sep 14, 2026
The approval expands Pharming's addressable U.S. market for Joenja into a younger pediatric APDS population, supporting incremental revenue expectations and reinforcing the drug's first-mover position in the indication. Broader market impact is limited given the rarity of APDS, but the milestone reduces regulatory uncertainty for Pharming and could modestly lift sentiment toward the stock.
The U.S. United States — Food and Drug Administration approved Joenja (leniolisib), developed by Pharming Group, for children aged 4 to 11 years weighing at least 27 kg with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency. The approval, announced September 11, 2026, expands Joenja's existing U.S. indication, which had covered adults and pediatric patients aged 12 and older since March 2023, and makes it the first FDA-approved treatment for this younger age group. The newly approved 40 mg and 50 mg twice-daily doses are expected to become available to eligible pediatric patients in the United States in October through Pharming's specialty distribution and patient-support network. The decision was supported by data from a multinational, open-label, single-arm Phase 3 study in children aged 4 to 11 with APDS, which over 12 weeks demonstrated reduced lymphadenopathy and increased naive B cells, indicating improvement in the underlying immune defect. The safety profile was consistent with prior Joenja experience, with treatment-emergent adverse events mild to moderate and no drug-related serious adverse events reported. The approval follows an earlier setback: in February 2026 Pharming received a complete response letter citing an analytical method issue for production batch testing and potential underexposure in lower-weight pediatric patients, and the FDA accepted the resubmitted application in June. Pharming submitted a separate supplemental application on July 30, 2026, seeking approval of lower Joenja doses for children aged 4 to 11 weighing 13 kg to less than 27 kg.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard